Healthcare venture capital firm EHA Impact Ventures has announced a $100,000 follow-on investment in medical technology developer Ananya Health. The capital will support efforts to secure product clearance from the US Food and Drug Administration (FDA).
The injection marks the third investment by the fund in Ananya Health. The transaction reinforces its strategy of providing patient capital to female-led businesses addressing key healthcare challenges across Africa.
Ananya Health is developing a battery-powered cryoablation device designed to freeze abnormal cervical cells before they turn cancerous. Traditional treatment requires specialist physicians, cryogen gas, and high capital expenditure, which restricts preventative care in low-resource settings.
Read also: Weak data foundations could derail Nigeria’s AI ambitions, expert warns
The portable device eliminates operational constraints, enabling any clinician trained in pelvic examinations to conduct the procedure. Patients can receive treatment from nurse-midwives at primary healthcare centres rather than facing referral to specialist hospitals.
“Every clinical milestone
This post was originally published on this site.
